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Abstract
Background. Surgery for colorectal liver metastases (CRLM) can be expected to be associated with a significant rate of
thromboembolic complications due to the performance of long-duration oncologic resections in patients aged 60 years.
Aims. To determine the prevalence of clinically significant thrombotic complications, including deep venous thrombosis
(DVT) and pulmonary embolus (PE), in a contemporary series of patients undergoing resection of CRLM with standard
prophylaxis. Material and methods. A prospectively maintained database identified patients undergoing resection of CRLM
from January 2000 to March 2007 and highlighted those developing thromboembolic complications. In addition, the
radiology department database was reviewed to ensure that clinically suspicious thromboses had been confirmed
radiologically by ultrasound in the case of DVT or computed tomography for PEs. Results. During the period of the
study, 523 patients (336 M and 187 F) with a mean age of 65 years underwent resection. A major hepatectomy was
performed in 59.9%. One or more complications were seen in 45.1% (n236) of patients. Thrombotic complications were
seen in 11 (2.1%) patients: DVT alone (n4) and PE (n7). Eight of 11 thrombotic complications occurred in patients
undergoing major hepatectomy, 4 of which were trisectionectomies. Patients were anti-coagulated and there were no
mortalities. Conclusions. The symptomatic thromboembolic complication rate was lower in this cohort than may be expected
in patients undergoing non-hepatic abdominal surgery. It is uncertain whether this is due entirely to effective prophylaxis or
to a combination of treatment and a natural anti-coagulant state following hepatic resection.
Introduction
Venous thromboembolism in terms of deep venous
thrombosis (DVT) or pulmonary embolism (PE) is a
well-recognized cause of significant morbidity in
patients undergoing resectional surgery for carcino-
mas [14]. The relative risk of thrombosis compared
to patients without tumors is 4 times, increasing to
6.5 times for patients who have also received che-
motherapy [5]. Furthermore, patients with throm-
boembolic disease have a 3-fold risk of pulmonary
embolism. A number of risk factors for thromboem-
bolism have been recognized (Table I) [6]. The
precise reason for the increased prevalence of throm-
boembolic events in patients with cancer is unclear,
although in many cases the thromboembolism is
attributed to a hypercoaguable state seen as part of
the paraneoplastic syndrome.
When surgical resection is also factored into the
equation, the risk is further increased [710]. The
reasons for the increased risk in the perioperative
period include immobility and venous trauma as a
result of central venous cannulation. The risk of
thromboembolic complications in patients with cancer
undergoing surgery is difficult to quantify given the
heterogeneity of tumors. The overall risk of asympto-
matic DVT has been placed at 2040%, increasing
further in the presence of additional risk factors,
mostly a past medical history of DVT or PE [4].
What is not clear is whether the increased thrombo-
tic risk is equal for all tumor types. The risk is said to
be high for malignant brain tumors and adenocarci-
nomas of the ovary, colon, stomach, pancreas, pros-
tate, lung, and kidney [1113]. There are few data on
the risk of DVT and PE in the context of hepatic
resection for colorectal liver metastases (CRLM). In a
series of 1803 patients undergoing hepatic resection,
1021 of which were for colorectal metastases, Jarnagin
and colleagues noted PEs in 16 patients (0.9%) and
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DVTs in 24 (1.3%) [14]. Yates et al., in a small series
of 99 resections for primary and secondary malignan-
cies, noted a much higher rate of thrombotic compli-
cations, with 7 (7.1%) events, all of which were seen in
patients with secondary tumors [15].
The recognition and appreciation of the high risk
of thrombotic complications in patients undergoing
surgery has led to the introduction of thrombopro-
phylaxis protocols, including both mechanical and
pharmacological measures. Patients with cancer are
among the group considered most at risk according
to the American Association of Chest Physicians [4],
since in addition to the presence of cancer most
patients are aged 40 or older.
The aims of this study were to document the
prevalence of DVT and PE occurring in a contem-
porary cohort of patients undergoing liver resection
for CRLM in whom prophylaxis had been prescribed,
and to investigate whether the presence of throm-
boembolic disease has any bearing on patient out-
come.
Patients and methods
All patients with CRLM undergoing hepatic resection
at St. James’s University Hospital (SJUH), Leeds,
United Kingdom, during the period January 2000
to March 2007 were identified from a prospectively
maintained hepatobiliary database.
The database was reviewed and the data collected
included patient demographics (age and gender); a
past medical history of thrombotic disease (DVT or
PE); and the extent of the resection performed. In
addition to inpatient follow-up, all events occurring
after the patient left hospital were also collated and
analysed.
In addition, the radiology department database was
reviewed to ensure that clinically suspicious throm-
boses had been confirmed radiologically by ultra-
sound in the case of DVT or CT for PEs.
During this time period, patients undergoing resec-
tion received a combination of low-molecular weight
heparin, thromboembolic deterrent stockings and
perioperative intermittent pneumatic compression as
prophylaxis against venous thrombosis.
Categorical data were presented as frequency and
proportions (%) and were analysed using the Pearson
chi-squared test. Univariate analysis was performed to
assess for a significant difference in clinico-pathologi-
cal characteristics that influenced the development of
thromboembolic complications. All statistical analyses
were performed using SPSS for WindowsTM version
15.0 (SPSS Inc, Chicago, Ill., USA), and statistical
significance was taken at the 5% level.
Results
During the period of the study, 523 patients under-
went resections for CRLM. There were 336 (64%)
men and 187 (36%) women, and the median age at
operation was 65 years (range 3291 years).
Only four patients had a past medical history of
thromboembolic disease, including four of DVT with
associated PE and one of isolated DVT. Only one of
this subgroup of patients was taking warfarin at the
time of admission for liver resection.
Three-hundred-and-ten (59.9%) patients under-
went a major hepatectomy (3 or more Couinaud
segments) with lesser anatomical or non-anatomical
hepatic resections performed in the remaining 213
(40.1%) patients. Overall, 279 (53%) patients had
hepatic resection performed for bilobar disease, and
348 (29%) had multiple tumors.
Thrombotic complications were observed in 11
(2.1%) patients (7 M and 4 F). Four presented with
symptomatic DVTs and the remaining seven with
respiratory symptoms leading to the diagnosis of PE.
Seven patients were diagnosed during their initial
hospitalization, and the remaining patients (2 DVT
and 2 PE) presented to the primary care services and
were re-referred to the HPB service for investigation
and management.
In all cases of suspected DVT, a Doppler ultra-
sound scan was performed, and in all cases of
suspected PE a CT scan of the chest. In addition, a
Doppler scan was performed to document the extent
of the lower limb thrombus.
Potential risk factors for venous thrombosis were
assessed but no significant factors were identified
apart from a previous history of thromboembolic
disease (Table I).
Discussion
The primary finding of this study is that in a
contemporary series of patients undergoing predomi-
nantly major liver resections after receiving prophy-
laxis, the rate of symptomatic thromboembolic
disease is 2.1%. This is the first study specifically to
address the issue of thromboembolic disease in
patients undergoing liver resection for CRLM. The
results were almost identical to the Memorial Sloan-
Kettering series, in which all patients undergoing
hepatic resection were included [14]. Interestingly,
none of the recent series from large institutions has
included details of thrombotic complications in the
results section [1619].
Despite these relatively low rates of thromboem-
bolic events, the recent series reported by Yates et al.,
with a 7.1% rate of thromboembolic complications, is
of concern [15]. There are also several papers high-
lighting the risk of thromboembolic complications
following living donor liver transplantation as the
consequences in this scenario are greater [20,21].
All these patients have normal livers and are healthy
individuals and thus should have a lower risk of
thrombosis than patients undergoing resection of liver
metastases. Bezeaud et al. investigated the etiology
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of the hypercoagulability observed in living donors
and confirmed dysregulation of hemostasis with an
increase in thrombin-antithrombin complexes (10-
to 30-fold) and P selectin (1.5- to 2-fold) following
surgery but found no difference between living donors
and patients undergoing resection of benign liver
tumors who acted as a control group. Levels of
both, however, were higher in the group of 4 patients
experiencing thromboembolic events compared to the
16 who did not. Unfortunately, no comparison was
made with patients undergoing resection of malignant
disease [22].
One factor highlighted in the literature is the degree
of uncertainty as to whether the correct thrombopro-
phylaxis is actually prescribed. Arnold et al. noted
that two-thirds of patients had either inadequate or
no thromboprophylaxis even though this was indi-
cated in relation to ACCP guidelines [23]. In a
retrospective series such as this, it is not possible to
confirm whether low molecular weight heparin was
administered correctly, but thromboprophylaxis has
been part of the perioperative protocol for all patients
undergoing hepatic resection.
Given that almost all the patients are high risk
according to the classification published by Geerts
and colleagues [4], in that the vast majority are over
40 years of age and undergoing major oncological
surgery, the rate of 2.1% would appear acceptable
compared to other surgical disciplines. In this series,
only a past history of DVT/PE was associated with a
higher risk of thromboembolic disease.
The rate of venographically confirmed DVT in
patients undergoing abdominal cancer surgery in the
absence of prophylaxis has been reported as being
between 20% and 40%, rising to 4060% in the
presence of additional risk factors [6]. Although the
prevalence of symptomatic DVT is significantly less
(1:5 to 1:10), natural history studies have demon-
strated a progression, thus indicating a definite benefit
for thromboprophylaxis [24].
In a meta-analysis of 59 studies, Mismeti and co-
workers showed that the use of low-molecular weight
heparin in general surgical patients can reduce the
risk of thromboembolic disease by up to 72% [25]. In
relation to oncological abdominal and pelvic surgery,
the enoxaparin and cancer (ENOXACAN) study
demonstrated that the use of prophylaxis for 1 month
reduced the incidence of venographically detected
thromboembolic events to 4.8% compared to 12%
with conventional therapy [26].
In the light of this study and other evidence, the
current ACCP recommendations suggest that, for









B40 5 (1%) 0 (0%) NS
]40 507 (99%) 11 (100%)
Gender
Male 329 (64.3%) 7 (63.6%) NS
Female 183 (35.7%) 4 (36.4%)
History of DVT/PE
Yes 3 (0.6%) 2 (18.2%) pB0.05
No 509 (99.4%) 9 (81.8%)
History of CVD
Yes 110 (21.5%) 2 (18.2%) NS
No 402 (78.5%) 9 (81.8%)
History of stroke/TIA
Yes 9 (1.8%) 0 (0%) NS
No 503 (98.2%) 11 (100%)
Neoadjuvant chemotherapy
Yes 90 (17.8%) 2 (18.2%) NS
No 421 (82.2%) 10 (81.8%)
Distribution
Bilobar 343 (67%) 7 (63.6%) NS
Unilobar 169 (33%) 4 (36.4%)
Number of tumors
Multiple 341 (58%) 7 (63.6%) NS
Single 171 (42%) 4 (36.4%)
Extent of resection
Major 304 (59.4%) 6 (54.5%) NS
Minor 208 (40.6%) 5 (45.5%)
CVDcardiovascular disease; TIAtransient ischemic attack.
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patients undergoing major abdominal cancer surgery,
the thromboprophylaxis should be continued post-
operatively for a period of 2835 days [4]. The
recently released American Society of Clinical Oncol-
ogy (ASCO) guidelines are in keeping with these
recommendations [27].
The rate of thromboembolic disease of 2.1% in this
study appears very acceptable in comparison to these
data; however, it must be remembered that this is
a clinical and not a screened rate and thus the true
figure for asymptomatic disease may be 510 fold
higher, i.e. in the order of 1020%. It has not been our
unit policy to prolong prophylaxis; indeed, the ma-
jority of events have occurred while individuals have
been inpatients, but this policy is currently being
audited.
Conclusions
The rate of symptomatic thromboembolic disease in
this high-risk cohort receiving mechanical and chemi-
cal prophylaxis was acceptable and comparable to
the limited clinical data currently available on the
topic. Given the recent guidelines on prolongation of
therapy postoperatively, further studies will be re-
quired to determine whether this is required and
indeed beneficial for patients undergoing resection of
the colorectal liver metastases.
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